Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Xbrane And Stada Seek Fresh Ranibizumab Partner In North America

New Search For Commercialization Alliance Comes After Bausch+Lomb Drops Deal

Executive Summary

Xbrane and Stada have announced that they are seeking a new North American partner for their biosimilar ranibizumab candidate after agreeing to discontinue a deal with Bausch+Lomb.

You may also be interested in...



Xbrane Drops Keytruda Rival As It Pares Down Pipeline And Personnel

Swedish biosimilars developer Xbrane Biopharma has revealed that it is dropping development of its planned Xtrudane pembrolizumab biosimilar to Keytruda, as part of a move towards a more “focused development portfolio.” At the same time, the firm has announced job cuts as part of a new cost-savings scheme designed to help the firm “achieve a positive cash flow as soon as possible.”

Stada’s Owners Hold ‘Initial Exploratory Talks’ For Potential Sale

For the first time, privately-owned Stada has acknowledged the potential for a sale of the business – six years after the private equity duo Bain Capital and Cinven announced a deal worth upwards of €5.4bn for the German firm.

Xbrane Gets Action Date As Ranibizumab Filing Accepted By FDA

Xbrane has announced the formal acceptance by the US FDA of its re-filed ranibizumab biosimilar, developed in collaboration with Stada and licensed in North America to Bausch + Lomb.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152872

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel